MedTrace Logo

The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

NCT01225549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-04-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.

Conditions

Interventions

DRUG

AZD5423

Suspension for nebulisation once daily 7 days

DRUG

Budesonide 200 microgram

Dry powder for inhalation twice daily 7 days

DRUG

Placebo

Solution for nebulisation once daily 7 days

DRUG

Placebo

Solution for nebulisation once daily 7 days

Sponsors & Collaborators

Principal Investigators

  • Christer Hultquist · AstraZeneca R&D, Mölndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01225549 on ClinicalTrials.gov